Lead Product(s) : Tucidinostat,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUYABIO Shares Positive Phase 2 Data On HBI-8000 and Nivolumab for Melanoma
Details : HBI-8000 (chidamide) is a class I HDAC inhibitor, in combination with nivolumab is being evaluated for the treatment of anti-PD(L)1-naive advanced melanoma.
Product Name : Hiyasta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2024
Lead Product(s) : Tucidinostat,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in Japan
Details : Hiyasta (HBI-8000) is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer. it targets class I histone deacetylases and suppresses expression of viral oncogene HTLV-I bZIP factor, NF-kB and the inflammasome in...
Product Name : Hiyasta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Meiji Seika Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : HUYABIO will complete the development of HBI-8000 for PTCL and ATL in Japan for commercialization by Meiji who will hold exclusive sales and marketing rights.
Product Name : Hiyasta
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 01, 2020
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Meiji Seika Pharma
Deal Size : Undisclosed
Deal Type : Collaboration